Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Immunovant (IMVT – Research Report), retaining the price target of ...

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

Analyst Brian Cheng of J.P. Morgan maintained a Buy rating on Immunovant (IMVT – Research Report), with a price target of $46.00.Invest with ...

KBC Group NV boosted its position in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 60.1% in the 4th quarter, ...

SG Americas Securities LLC increased its position in argenx SE (NASDAQ:ARGX – Free Report) by 6.2% in the 4th quarter, ...

Immunovant stock down on dismal third-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.

Denver Location Boasts Private Infusion Suites for Addressing Patients’ Specialty Therapy Needs Soleo Health, an innovative ...

Guggenheim Securities updated their outlook on Immunovant (NASDAQ:IMVT) shares, raising the price target from $44.00 to $46.00 while maintaining a Buy rating on the stock. Currently trading at $23.23, ...

Discover a study that explores the effectiveness of JAK inhibitors to treat dermatological autoimmunity for people with Down ...

These findings support clinical practice to expand screening for autoimmune diseases in women with POI as already recommended for hormones and antibodies associated with adrenal and thyroid disease ..